In the phase 2/3 trial, 437 study participants had “well-tolerated” reactions to the booster candidate, mRNA-1273.214, according to a June 8 news release.
At a 97.5 percent confidence level, the treatment “increased neutralizing geometric mean titers against omicron approximately eightfold above baseline levels.” The 50-microgram booster also had statistically significant results combating other variants of concern, including alpha, beta, gamma and delta, the release said.
Moderna CEO Stéphane Bancel said the company plans to have the booster candidate approved and distributed by late summer.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
